Ionis Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2025. The company recorded $32.0 million in net product sales from TRYNGOLZA (olezarsen) in the third quarter, representing nearly a 70% increase over the prior quarter. Cash, cash equivalents, and short-term investments totaled $2.2 billion as of September 30, 2025, compared to $2.3 billion on December 31, 2024. The company's working capital decreased over the same period, primarily due to the reclassification of 0% convertible notes as a current liability. Business developments during the period included the launch of TRYNGOLZA and DAWNZERA (donidalorsen), with the latter described as having an encouraging start. Ionis announced positive topline Phase 3 results for olezarsen in severe hypertriglyceridemia and for zilganersen in Alexander disease, with regulatory filings planned in the coming months. The company anticipates independent launches of olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease in 2026. Ionis increased its 2025 financial guidance, citing continued strength across its business and expects to reach cash flow breakeven in 2028.